Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2019-06-11 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Notification of Preliminary Results
Regulatory Filings Classification · 1% confidence The document is very short (2495 characters) and its primary purpose is to announce *when* the preliminary results will be released ('Evgen Pharma... will announce its preliminary results for the year ended 31 March 2019 on Thursday 13 June 2019'). It is not the results themselves, nor is it a full Annual Report (10-K) or Interim Report (IR). It is an announcement about the publication of a future report. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports. The presence of the RNS Number and the RNS footer further confirms it is a regulatory announcement.
2019-06-11 English
Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
Regulatory Filings Classification · 1% confidence The document is a press release issued by Verona Pharma plc on June 4, 2019, announcing the initiation of a Phase 2 dose-ranging trial for ensifentrine via MDI formulation in COPD patients. It details the trial design, anticipated data timelines (H2 2019, Q1 2020), and provides context on the market and the drug's development status (Phase 2b nebulized trial also ongoing). This content—announcing clinical trial progress, market context, and future plans—is characteristic of an Earnings Release (ER) or a general press release announcing operational updates. Since it focuses on operational/clinical progress rather than just summarizing period-end financial results (which would be ER), and it is not a full financial report (10-K or IR), it fits best as an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the structure and content (announcing a trial start and providing timelines), it strongly resembles an Earnings Release or a significant operational update often bundled with earnings announcements. However, since it is a standalone announcement of clinical progress and market opportunity, and not explicitly tied to a quarterly reporting period summary, the most appropriate classification among the options for a significant operational/clinical update press release is 'Earnings Release' (ER), as these often contain forward-looking operational news, or 'Regulatory Filing' (RNS) as a general announcement. Given the focus on clinical trial initiation and future data reporting, ER is often used for such operational news releases, but RNS is the general regulatory fallback. Since it is a formal announcement via GlobeNewswire detailing clinical progress, it is a type of regulatory disclosure. If it were purely financial summary, ER would be perfect. As it is a specific operational update, RNS (Regulatory Filings/General Announcement) is a safe classification, but ER often covers clinical trial updates too. Let's re-evaluate based on definitions. It is not a full financial report (10-K/IR), nor a presentation (IP), nor a management discussion (MDA). It is an announcement of an event (trial initiation). This type of announcement is often classified as RNS if it doesn't fit elsewhere. However, many companies issue these clinical updates around earnings time, making ER plausible. Given the lack of explicit financial period reporting (like Q1 results), RNS is the most neutral fit for a specific operational announcement that isn't a core financial report or a specific event like DIV or DIRS. I will classify it as ER because clinical trial updates are frequently released alongside or in lieu of detailed financial reports when reporting operational progress, and it contains forward-looking statements typical of such releases.
2019-06-04 English
Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference
Report Publication Announcement Classification · 1% confidence The document is a press release dated May 30, 2019, announcing that the management team of Verona Pharma plc will present at the Jefferies 2019 Global Healthcare Conference on June 5th. It details the presenter, date, time, and location. It also includes standard company background information, forward-looking statements, and contact details. This type of announcement, which informs investors about management participation in an external industry conference, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or an announcement about future investor engagement. Since the core purpose is to announce management's participation in a specific investor event (a conference presentation), it aligns best with the Investor Presentation (IP) category, which covers materials for investors, or potentially a Regulatory Filing (RNS) if it were purely administrative. Given the context of presenting company information to investors at a specific event, IP is the most fitting specific category, although it is an announcement *about* a presentation rather than the presentation itself. However, looking at the definitions, there is no specific code for 'Conference Presentation Announcement'. It is not an Earnings Release (ER), nor a formal regulatory filing like 10-K or IR. It is an announcement intended for investors regarding future engagement. Since it is an announcement about management presenting company information to investors, it is closely related to Investor Presentation (IP). If it were purely a notice of an event without substantive company/strategy updates, RNS might apply, but the inclusion of product pipeline details (ensifentrine) leans towards IP.
2019-05-30 English
PDMR Dealing
Director's Dealing Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states it is providing information in accordance with the EU Market Abuse Regulation regarding a transaction by a person closely associated with a director (CFO). The content details the purchase of ordinary shares by the CFO's spouse. This type of insider transaction reporting, specifically detailing director/executive dealings, maps directly to the 'Director's Dealing' category (DIRS). Although it is distributed via RNS, the specific content dictates the more precise classification.
2019-05-29 English
Change to Director Shareholding
Director's Dealing Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange'. The content details a 'Change to Director Shareholding' for a non-executive director, Luke Cairns, resulting from administrative proceedings of a stockbroker. This type of transaction report by a director or executive is specifically classified as Director's Dealing (DIRS). Although RNS is present, DIRS is the more specific category for director share transactions.
2019-05-28 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with 'RNS Number : 8817Z' and contains the standard format for a 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification. Although it is distributed via RNS, the core content is a specific regulatory filing about share ownership changes, making 'MRQ' (Major Shareholding Notification) the most precise classification over the general 'RNS' fallback. The date of notification is May 22, 2019.
2019-05-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.